Press Ganey launches seal for data integrity

Press Ganey has introduced the transparency Seal of Integrity, which will be used to assure providers, physicians and patients that patient experience data are scientifically rigorous and objectively presented using a standardized rating system.

The seal aims to help consumers confidently assess provider performance, helping to ensure community trust and a reliable understanding of the quality of care being delivered by an organization’s physicians.   

“As more and more patients turn to online physician ratings when selecting a provider, we are seeing healthcare organizations implementing strategies to ensure that the ratings available are objective, standardized evaluations of the patient experience,” said Patrick T. Ryan, CEO of Press Ganey. “The critical foundation of a successful transparency program is robust data capture, and Press Ganey is committed to delivering an accurate representation of provider performance. When healthcare consumers see the Seal of Integrity, they will know they are looking at a reliable review of that provider--empowering them to make informed decisions about where to seek care.”

To receive recognition with the Seal of Integrity, data published by organizations must meet scientifically-rigorous standards and be certified to reflect the following requirements:

  • Reliability score of 0.97 for star rating measure
  • Compliance with one standardized star rating system
  • Assurance of 30 or more survey returns per physician
  • Commitment to reporting every survey response
  • Posting of all comments, suppressing only those with privacy or libelous information
Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.